COVID-19 Update: The Diabetes Connection, WHO Concerned about BA.2
Viral infections can have a broad range of side effects, such as myocarditis, and COVID-19 is no different. There is evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, an autoimmune disease most commonly...
FDA approves Four Cancer Clinical Trials
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment, including Sonnet BioTherapeutics and Adagene. Sonnet BioTherapeutics evolved into a clinical biopharmaceutical...
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Arrowhead Pharmaceuticals, Inc. has announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for...
CDE Approves the Inclusion of Hexvix® in the Clinical Real-world Evidence Pilot Study
Asieris Pharmaceuticals, in accordance with advice from the National Medical products Administration Center for Drug Evaluation (CDE), has approved the inclusion of Asieris’s drug Hexvic®, a drug for the diagnosis of bladder cancer, in the clinical real-world world...
Hoth Therapeutics: Orphan Drug Designation for HT-KIT
Hoth Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HT-KIT to treat mastocytosis. Mastocytosis is a rare condition caused by an abnormal accumulation and activation of mast cells in the skin, bone...
C4 Therapeutics: Orphan Drug Designation for CFT8634
C4 Therapeutics (C4T) has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 to treat soft tissue sarcoma. Soft tissue sarcoma is a rare type of cancer that begins in the tissues that connect, support, and...